RaQualia Pharma Inc.
TRPV4 antagonist (pyrimidin-4(3H)-one derivative) patent allowance in Korea
Received patent allowance for a TRPV4 antagonist in Korea. Eligible for patent allowance across all five major patent offices, strengthening the intellectual property portfolio. No direct impact on 2026 performance.
Key Figures
- Patent allowances: Korea
- Patent allowances across all five major patent offices
- Direct impact on performance: Unknown (stated no impact for the 2026 fiscal year)
AI要約
Key points of the news
The material patent application for the TRPV4 antagonist in Korea (application number 10-2022-7040115) has been allowed, positioning the company's intellectual property portfolio for protection across all five major patent offices. The target drug has TRPV4 antagonistic action and shows promise in ocular, pain, and inflammatory models. It is stated that there will be no impact on the 2026 fiscal year results.
Future IP strategy and R&D activities
Continue collaborative research成果 with Gifu Pharmaceutical University under industry-academia collaboration, aiming to strengthen the patent portfolio and enhance long-term corporate value. Scholarly成果 such as 2023 publications and 2025 conference introductions will continue to be disclosed as indicators of potential value for the company.
RaQualia Pharma Inc.
Company overview · Stock price · Financial data · All IR
